TABLE 3.
Physician-reported clinical response for 46 patients treated with cefiderocol via the compassionate use program for an infection due to multidrug- or carbapenem-resistant Pseudomonas aeruginosa, stratified by cefiderocol MIC value
| MIC (μg/mL) | No. of patients | Physician-reported response (no. [row %]) |
||
|---|---|---|---|---|
| Response | No response/withdrawn from therapy | No report/unknown | ||
| ≤0.03 | 2 | 1 (50) | 1 (50) | 0 |
| 0.06 | 0 | 0 | 0 | 0 |
| 0.12 | 4 | 4 (100) | 0 | 0 |
| 0.25 | 10 | 6 (60) | 2 (20) | 2 (20) |
| 0.5 | 9 | 6 (67) | 1 (11) | 2 (22) |
| 1 | 4 | 3 (75) | 0 | 1 (25) |
| 2 | 9 | 5 (56) | 2 (22) | 2 (22) |
| 4 | 4 | 4 (100) | 0 | 0 |
| 8 | 3 | 3 (100) | 0 | 0 |
| 16 | 1 | 1 (100) | 0 | 0 |
| ≥32 | 0 | 0 | 0 | 0 |
| Total patientsa | 46 | 33 (72) | 6 (13) | 7 (15) |
a
If multiple baseline P. aeruginosa isolates with different cefiderocol MIC values were identified, the isolate with the highest cefiderocol MIC value was used.